Kishor Dabhi, MD
Internal Medicine · Colonial Heights, VANPI 1285749051
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.
Across 170 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$539
- Lilly USA, LLC$370
- GSK$363
- Novo Nordisk$328
- AbbVie$240
- Sanofi-aventis U.S. LLC$216
- plus $792 from 15 others
Across 19 payments — averaging $1963.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$37K
What the payments were for
- Food & beverage$2,79598%
- Education$532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 15 | $539 |
| Lilly USA, LLC | 25 | $370 |
| GSK | 24 | $363 |
| Novo Nordisk | 23 | $328 |
| AbbVie(2 entities) | 17 | $240 |
| Sanofi-aventis U.S. LLC | 15 | $216 |
| AstraZeneca | 12 | $168 |
| Pfizer | 8 | $127 |
| Esperion Therapeutics, Inc. | 4 | $78 |
| Biogen | 4 | $77 |
| Merck | 5 | $71 |
| Kowa Pharmaceuticals America, Inc. | 4 | $57 |
| Eisai Inc. | 3 | $44 |
| Abbott | 2 | $34 |
| Boehringer Ingelheim | 2 | $33 |
| Bayer | 2 | $33 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,849 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $77,118 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $53,901 |
| MounjaroTirzepatide | 32 | $40,214 |
| JardianceEmpagliflozin | 25 | $34,275 |
| JanuviaSitagliptin Phosphate | 25 | $32,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $27,362 |
| EntrestoSacubitril/Valsartan | 18 | $21,106 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $20,751 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $18,424 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $17,960 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $15,732 |
| EliquisApixaban | 16 | $13,679 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $9,385 |
| AzorAmlodipine Bes/Olmesartan Med | 22 | $8,938 |
| Levemir FlexpenInsulin Detemir | 13 | $5,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $328 | $77,11874 claims |
| MerckJanuvia, Janumet Xr | $71 | $53,49940 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $363 | $45,32260 claims |
| Lilly USA, LLCMounjaro | $370 | $40,21432 claims |
| Boehringer IngelheimJardiance | $33 | $34,27525 claims |
| PfizerEliquis, Paxlovid | $127 | $15,10929 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $3,75912 claims |
| AstraZenecaCrestor | $168 | $3,18013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Colonial Heights
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Gautam GulatiMc Lean$136K
- Francesse BatailleDumfries$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.